Current position

Fidelity Investments’s Merck (MRK) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

FMR LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2016Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares71.47MHighest verified quarter-end share count
Quarters reported37Verified quarters with shares above zero
What happened?

FMR LLC first reported Merck in Q3 2016. The reported position was increased and reduced across later filings. FMR LLC currently reports 45.44M shares. The latest verified filing showed: Bought 2.1% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 2.1% more+924.35K shares · 45.44M shares reported after the change
Filing context

Quarter-end price $128.50

Q1 2026
Bought 9.0% more+3.68M shares · 44.52M shares reported after the change
Filing context

Quarter-end price $120.29

Q4 2025
Bought 22.2% more+7.41M shares · 40.84M shares reported after the change
Filing context

Quarter-end price $105.26

Q3 2025
Bought 5.9% more+1.86M shares · 33.43M shares reported after the change
Filing context

Quarter-end price $83.93

Q2 2025
Sold 0.8% of the position−241.92K shares · 31.57M shares remained
Filing context

Quarter-end price $79.16

Q1 2025
Sold 14.9% of the position−5.55M shares · 31.81M shares remained
Filing context

Quarter-end price $89.76

Portfolio importance

How important is Merck in FMR LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.3%Q2 2026
Current rank#57of 5572 reported positions
Peak portfolio weight0.5%Q1 2024
Best historical rank#28Q1 2024
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$149.502026-09-21

Market context only; not an investor transaction price.

Latest filing quarter-end price$128.50Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

View Merck stock page →

Coverage is bounded to Fidelity’s top reported positions and material events rather than every security in each Form 13F. The consolidated FMR LLC filing includes multiple Fidelity investment managers. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.